Saracatinib difumarate    (DrugBank: Saracatinib)

1 disease
IDDisease name (Link within this page)Number of trials
272Fibrodysplasia ossificans progressiva1

272. Fibrodysplasia ossificans progressiva    [ 23 clinical trials,   21 drugs,   (DrugBank: 4 drugs),   10 drug target genes,   87 drug target pathways]
Searched query = "Fibrodysplasia ossificans progressiva", "FOP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 23 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-003324-20-NL
(EUCTR)
08/01/202016/10/2019A clinical trial to judge the safety, tolerability and effects on abnormal bone formation of reseach medication AZD 0530 (sarcatinib) in patients with FOPSaracatinib trial TO Prevent FOP - STOPFOP Fibrodyplasia Ossificans Progressiva (FOP)
MedDRA version: 20.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: Saracatinib
Product Code: AZD0530
INN or Proposed INN: Saracatinib
Other descriptive name: SARACATINIB DIFUMARATE
VU University Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
16Phase 2Netherlands